Accessing Combinatorial Effect of PARP Inhibitor with DNA Damaging Agent in Rhabdomyosarcoma at Single Cell Resolution
Combination therapies using cytotoxic drugs have revolutionized the treatment of pediatric rhabdomyosarcoma (RMS). However, cure rates have largely remained stagnant since their implementation. We have recently generated an optically-clear, immune-deficient zebrafish that can engraft human RMS tumors, with growth kinetics and histological features similar to those grown in immune-deficient murine models. However, the zebrafish model has additional powerful attributes including high fecundity, low maintenance cost and the ability to assess growth kinetics at single-cell resolution. PARP inhibitors (PARPi) are now used in the clinic for the treatment of triple negative breast cancer and ovarian cancer. More recently, it has been demonstrated that the addition of DNA-damaging agents potentiates PARPi cytotoxicity in a variety of cancer types, including Ewing sarcoma. To date, preclinical modeling of PARPi and DNA-damaging agents has yet to be studied in RMS.
Given that PARPi are now in clinical evaluation in children, are well-known to induce apoptosis in human RMS cell lines and potently synergize with DNA-damaging agents to elevate cancer cell killing in other sarcomas, this project aims to study if the combination of PARPi and DNA-damaging agents will be an effective therapy for pediatric RMS patients.
Aim 1 will elucidate an optimal combination of PARPi and DNA-damaging agents for human RMS cells using xenograft studies into immune-deficient zebrafish. Aim 2 will investigate mechanism(s) of drug action at single cell resolution. Aim 3 will validate the most efficient combination of PARPi and DNA-damaging agents for effects in human PDX models of RMS.